anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DNAs encoding the mammalian histamine H4 receptors have been cloned and characterized. These recombinant molecules are capable of expressing biologically active histamine H4 receptor protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The pharmacology of known histamine ligands is demonstrated. The recombinant protein may be purified from the recombinant host cells. In addition, recombinant host cells are utilized to establish methods to identify modulators of the receptor activity, and receptor modulators are identified.
Skin fibrosis, the most obvious clinical manifestation of systemic sclerosis (SSc), has a high unmet need for treatment. Xanthohumol (Xn) has been shown to have beneficial effects on fibrotic diseases, but its efficacy in SSc remains unreported. This study aims to elucidate the effects and mechanisms of Xn on collagen synthesis in SSc skin fibroblasts (SScF). We found increased collagen production in SScF cultured in vitro, accompanied by dysregulated levels of oxidative stress. Cell experiments showed that Xn inhibited cell proliferation and promoted apoptosis. In addition, Xn was shown for the first time to upregulate reactive oxygen species (ROS) and nuclear factor erythroid 2-related factor 2 (Nrf2)levels in SScF, and when combined with the ROS scavenger N-acetylcysteine (NAC), Nrf2 expression was decreased. Importantly, we demonstrated that Xn significantly attenuated collagen synthesis by blocking the fibrotic classical transforming growth factor beta 1 (TGFβ1)/Smad3 pathway, which interestingly was upregulated when combined with the Nrf2 inhibitor 385. Taken together, Xn suppressed the TGFβ1/Smad3 pathway to ameliorate collagen overproduction by promoting ROS-induced oxidative stress damage and activating Nrf2, suggesting that Xn administration may be an emerging therapeutic strategy for skin fibrosis in SSc.
UNLABELLED: This letter to the editor aims to prompt medical students, residents, and sleep medicine fellows to actively support the implementation of delayed school start times in middle and high schools, considering the significant impact it holds for children and adolescents. During puberty, research has demonstrated that circadian changes result in a sleep-phase delay among adolescents, leading them to sleep and wake up later compared to other age groups. This, coupled with early school start times, contributes to sleep deprivation within this patient population, increasing the likelihood of drowsy driving accidents, mental health problems, academic underperformance, and a predisposition to chronic illnesses like diabetes mellitus and hypertension. As medical students, residents, and fellows in the field of sleep, we must prioritize advocating for healthy sleep and addressing the issue of early school start times. By doing so, we can safeguard the future of medicine and society, ensuring the well-being and success of our middle and high school students.
CITATION: Hernandez VK. To the editor: early school start times in middle and high schools have profound implications for children and teens. J Clin Sleep Med. 2024;20(4):671-672.
A method is provided for in vivo or ex vivo delivery of a preparation of powdered nucleic acid molecules into vertebrate tissue for transformation of cells in the tissue using needleless injection techniques. The method can be used to deliver therapeutically relevant nucleotide sequences to cells in mammalian tissue to provide gene therapy, elicit immunity or to provide antisense or ribozyme functions. A method for providing densified processed pharmaceutical compositions is also described. The method is used to convert non-dense pharmaceutical powders or particulate formulations into densified particles optimally suited for transdermal delivery using a needleless syringe. The method is also used to optimize the density and particle size of powders and particulate formulations for subsequent transdermal delivery thereof. Densified pharmaceutical compositions formed by the present methods are also provided.
A method of detecting a member of the taxa actinomycetes is provided. A method also is provided for detecting mycothiol or precursor thereof. An antibody is provided which binds to mycothiol or a mycothiol precursor. A method is further provided for diagnosis of a subject having or at risk of having an actinomycetes-associated disorder. A method is also provided for identifying a sample with altered production of mycothiol or a precursor thereof. A method is provided for detecting mycothiol or precursor thereof in a bacterial colony. Kits are also disclosed which are useful for detecting the presence of mycothiol or precursor thereof in a sample.
INTRODUCTION AND OBJECTIVE: Patients with congenital diaphragmatic hernia (CDH) can have up to 40 times more frequency of muskuloskeletal deformities and decreased perception of physical activity tan their pairs. The objective of this study is to evaluate the safety and efficacy of an individualized exercise program in late adolescents and young adults with repaired CDH, as well as a description of their basal status.
MATERIAL AND METHODS: Non randomized prospective trial of 13 patients with repaired CDH between 1997-2005. An initial physical exploration and a pre-post assessment of bioimpedance (BIA), dynamometry, maximal inspiratory and expiratory pressure (MIP/MEP), 6-minute walk test (6MWT), physical activity level (IPAQ) and quality of life (QoL) was made. The training program last for 4 weeks. For the statistical analysis, the Student's t test for paired samples and Wilcoxon test were used.
RESULTS: 77% (n=10) were male with a mean age of 19.23±2.13 years. In baseline BIA, 62% (n=8) had truncal sarcopenia that improved in -0.43±0.58, and P=.016. MIP, MEP, 6MWT and QoL tests increased by -7.27±8.26 cmH2O, P=.008; -11.91±10.20 cmH2O, P=.002; -70.63±17.88 m, P=.001; -42,19±26.79, P=.00 respectively. The IPAQ did not change significantly (P=0.86), however the time dedicated to muscle strengthening increased. No adverse effects were reported.
CONCLUSIONS: A personalized rehabilitation program is safe and could improve the respiratory muscle strength and truncal sarcopenia as well as the submaximal effort capacity in late adolescents and young adults with repaired CDH.
PURPOSE:To easily and efficiently eliminate cancer-inducing active oxygen or radical existing in a food or generated in living body by using vegetables as eliminating agent. CONSTITUTION:For example, scorching often occurs in the heat cooking of a food, which is the thermal decomposition product of a proteineous food or a polycyclic aromatic hydrocarbon, etc., from a carbohydrate food. Cancer- inducing active oxygen or radical is generated in the course of metabolism of the above product. In addition to the above, active oxygen is generated in living body by the metabolism of various harmful substances. The generated active oxygen or radical can be efficiently eliminated by the use of vegetables. Preferable examples of the vegetables are spinach, radish leaf and vegetable juice.
TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.
Endothelial progenitor cells (EPCs) play a crucial role in maintaining vascular health and aiding in the repair of damaged blood vessels. However, the specific impact of EPCs-derived exosomes on vascular endothelial cell injury caused by lipopolysaccharide (LPS) remains inadequately understood. This study aims to explore the potential benefits of EPC-exosomes in mitigating LPS-induced vascular injury and to elucidate the underlying mechanism. Initially, EPCs were isolated from mouse peripheral blood, and their identity was confirmed through flow cytometry and immunocytochemistry. Subsequently, the exosomes derived from EPCs were identified using transmission electron microscopy (TEM) and western blot analysis. A sepsis model was induced by subjecting brain microvascular endothelial cells (BMECs) to LPS-induced injury. Both EPC and their exosomes demonstrated a significant increase in BMECs proliferation, reduced apoptosis, decreased levels of pro-inflammatory factors (TNF-α, IL-6, and caspase-3), and enhanced sprouting and angiogenesis of BMECs. Notable, the Exosomes demonstrated a more pronounced impact on these parameters. Furthermore, both EPCs and Exosomes exhibited significantly increased levels of miR-126a-5p, with the Exosomes showing a more substantial enhancement. These findings suggest that supplementing exosomal miR-126a-5p from EPCs can provide protective effects on BMECs, offering a potential therapeutic option for treating sepsis-induced microvascular endothelial cell injury.
PROBLEM TO BE SOLVED: To obtain a cosmetic oil giving little oily and sticky feeling to the skin and excellent feeling in use and exhibiting excellent emollient effect by adding a specific amount of a specific compound to an oily agent composed mainly of a triglyceride. SOLUTION: This cosmetic oil is prepared by compounding a cosmetic oil containing 5-50wt.% of an oily agent composed mainly of a triglyceride with 0.1-10 pts. (based on 1 pt. of the oily agent) of an isostearic acid ester. The isostearic acid ester is preferably an ester between isostearic acid and a diglycerol and/or an ester between isostearic acid and a triglycerol. The sum of the oily agent composed mainly of triglyceride and the isostearic acid enter is preferably 20-99.5wt.% based on the total cosmetic oil. The oily agent composed mainly of triglyceride is e.g. olive oil, medform oil or rose hip oil.
Like group I, each participant will be trained on a conventional treadmill for (50 minutes) as follows: warming up by walking on the treadmill belt with a comfortable walking speed suitable for each participant for 5 minutes. The speed should be determined Then participants continue training on the treadmill for 20 minutes; no VR will be used or applied. Participants should get a 5-min break and then resume training on the treadmill again for 25 minutes.
The invention relates to a method for modelling a gut microbiome, comprising five steps. First, receiving phenotypic data, medical data, lifestyle data and metagenomic data for a set of individuals. Then, receiving phenotypic data, medical data and lifestyle data for a target individual. Next, constructing a vector of the phenotypic data, medical data and lifestyle data for all these individuals. Additionally, determining individuals, from the set of individuals, with maximum similarity to the target individual. Finally, generating at least one microbiome-scale community model based on the metagenomic data of the individuals with maximum similarity to the target individual. The at least one microbiome-scale community model generated provides a molecular fingerprint of gut microbiome activity by simulating food absorption by the gut microbiome. The molecular fingerprint of the activity of the gut microbiome comprises a metabolic flux vector, the metabolic flux vector comprising a distribution of the metabolic fluxes via the reactions of the microbiome-scale community model.
The present invention relates to genes, referred to herein as cell death-protective genes, which protect cells against programmed cell death by antagonizing the activities of genes which cause cell death. As described herein, a cell death-protective gene from the nematode  Caenorhabditis elegans , called ced-9, has been identified, sequenced, and characterized. ced-9 is essential for  C. elegans  development and apparently functions by protecting cells which normally live during development from programmed cell death. Mutations which constitutively activate and inactivate the ced-9 gene are also described. ced-9 was shown to function by antagonizing the activities of the cell death genes, ced-3 and ced-4. As further described, the protein product of the human oncogene bcl-2 was found to have a similar sequence to the ced-9 protein. Methods and agents for both increasing and decreasing the occurrence of cell death are described that are potentially useful for diagnosis, prevention and therapy of diseases and conditions involving cell death; for the treatment of viral, parasitic, and other types of infection; and for killing organisms that are detrimental or potentially detrimental to the environment or to humans, pets, livestock, or agriculture.
Analgesic and anaesthetic compositions comprise promazine or a non-toxic acid addition salt thereof (e.g. the hydrochloride), the non-toxic acid addition salt of pethidine (e.g. the hydrochloride) and a non-toxic acid addition salt of hyoscine (e.g. the hydrobromide).  The compositions may be administered in the form of sterile solutions for injection, elixirs, tablets, capsules and suppositories.  The sterile solutions exemplified also include thimerosal (sodium ethylmercurithiosalicylate).
<P>PROBLEM TO BE SOLVED: To provide a system for controlling communication of medical imaging data.  <P>SOLUTION: A system for controlling the communication of medical imaging data is disclosed generally comprising, a computer, a plurality of sources of medical imaging data, a plurality of destination for medical imaging data communicated with the computer, and a touch-screen for simultaneously displaying a plurality of source icons and a plurality of destination icons controlled by the computer. The source icons correspond to the plurality of sources to allow a user to select a particular source of imaging data, and the destination icons correspond to the plurality of destinations to allow the user to select at least one particular destination for the imaging data. In certain embodiments, the touch-screen includes a display window for displaying medical images generated from the imaging data supplied by the presently selected source. In some embodiments, the touch-screen includes a plurality of controls associated with the presently selected source.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE: An Ixeris polycephala Cassini extract, and urs-12-ene and olean-12-en-3-ol isolated from the extract are provided to ensure excellent antibacterial activity against gram-negative bacteria, gram-positive bacteria, or helicobacter pylori, and to be used as an antibacterial composition and a therapeutic agent for treating disease caused by bacteria. CONSTITUTION: An antibacterial pharmaceutical composition contains an Ixeris polycephala Cassini extract as an active ingredient. The extract is prepared using water, C1-C4 alcohols, or a mixture thereof. The extract has antibacterial activity against one or more microbes selected from the group consisting of helicobacter pylori, Staphylococcus aureus, and E.coli. The antibacterial pharmaceutical composition contains one or more compounds selected from the group consisting of chemical formulas 1 and 2, as active ingredients. The compounds are isolated from the extract.
Phospholipase D (PLD) lipid-signaling enzyme superfamily has been widely implicated in various human malignancies, but its role and underlying mechanism remain unclear in nasopharyngeal carcinoma (NPC). Here, we analyze the expressions of 6 PLD family members between 87 NPC and 10 control samples through transcriptome analysis. Our findings reveal a notable upregulation of PLD1 in both NPC tumors and cell lines, correlating with worse disease-free and overall survival in NPC patients. Functional assays further elucidate the oncogenic role of PLD1, demonstrating its pivotal promotion of critical tumorigenic processes such as cell proliferation and migration in vitro, as well as tumor growth in vivo. Notably, our study uncovers a positive feedback loop between PLD1 and the NF-κB signaling pathway to render NPC progression. Specifically, PLD1 enhances NF-κB activity by facilitating the phosphorylation and nuclear translocation of RELA, which in turn binds to the promoter of PLD1, augmenting its expression. Moreover, RELA overexpression markedly rescues the inhibitory effects in PLD1-depleted NPC cells. Importantly, the application of the PLD1 inhibitor, VU0155069, substantially inhibits NPC tumorigenesis in a patient-derived xenograft model. Together, our findings identify PLD1/NF-κB signaling as a positive feedback loop with promising therapeutic and prognostic potential in NPC.
The invention provides a traditional Chinese medicine for treating vulvar leukoplakia and a preparation method thereof and belongs to the field of traditional Chinese medicine preparation techniques. The traditional Chinese medicine is prepared by using natural Chinese herbal medicines as raw material. The traditional Chinese medicine is characterized by comprising 30g of sophora flavescens, 30g of common cnidium fruit, 30g of rhizoma atractylodis, 20g of belvedere fruit, 20g of folium isatidis, 20g of astragalus membranaceus, 20g of blackberrylily rhizome, 20g of angelica, 20g of salvia miltiorrhiza, and 20g of schizonepeta. The preparation method includes: well mixing the Chinese herbal medicines according to a weight ratio, grinding into powder of 1-100 micrometers and packing with 10g per bag. Application of the traditional Chinese medicine includes: taking 10g to put into a cup, soaking with boiled water for 10 minutes, pouring into a basin, adding 1500ml warm water at 35-40 DEG C, hip bathing for 10-15 minutes, wetting gauze with the medicine for partial hot applying for 10-15 minutes, and slowly rubbing. The traditional Chinese medicine is applied 1-2 times a day for four weeks as a treatment course. Two treatment courses are needed to treat the vulvar leukoplakia. The traditional Chinese medicine for treating vulvar leukoplakia has the functions of clearing heat and itching relieving, promoting blood circulation to remove blood stasis and antisepsis and anti-inflammation; is convenient to prepare and use, lasting in medicine effect, free of side effects; and has rich raw material source, and is ideal therapeutic for treating vulvar leukoplakia.
Despite the widespread use of dental restorative materials, little information exists in the literature regarding their potential impact on bad breath. This in vitro study aims to fill this gap by investigating the influence of different restorative materials on the release of hydrogen sulfide (H2S). Thirteen diverse dental restorative materials, including composites, flowable composites, glass ionomer restorative materials, high-copper amalgam, and CAD-CAM blocks, were examined. Cellulose Sponge models were used as negative and positive control. All samples were prepared with a diameter of 5 mm and a height of 2 mm. Except for the negative control group, all samples were embedded into Allium cepa L., and the emitted H2S was measured using the Wintact W8802 hydrogen sulfide monitor. Surface roughness's effect on emission was explored by roughening the surfaces of CAD-CAM material samples, and gas emission was measured again. The data were statistically analyzed using the Kruskal-Wallis test and DSCF pairwise comparison tests. Fiber-reinforced flowable composite (EverX Flow), amalgam (Nova 70-caps), and certain composite materials (IPS Empress Direct, Tetric Evoceram, Admira Fusion X-tra) released higher H2S concentrations compared to the negative control. The H2S release period lasted longer in the same materials mentioned above, along with G-aenial Universal Injectable. Indirectly used materials, such as GC Cerasmart, Vita Enamic, and Vita YZ HT, demonstrated significantly lower emissions compared to other direct restoratives. Importantly, the surface roughness of indirect materials did not significantly affect peak H2S concentrations or release times. The study reveals variations in H2S release among restorative materials, suggesting potential advantages of indirect restorative materials in reducing H2S-induced halitosis. This comprehensive understanding of the relationship between restorative materials and halitosis can empower both dental professionals and patients to make well-informed treatment choices. Notably, there is evidence supporting the enhanced performance of indirect restorative materials for individuals affected by halitosis.
Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to "inhabit" life in that era, making a psychological leap to be the person they were at the end of the 1980s.
Hypoxic-ischemic encephalopathy (HIE) is a prominent cause of neonatal mortality and neurodevelopmental disorders; however, effective therapeutic interventions remain limited. During neonatal hypoxic-ischemic injury events, increased reactive oxygen species (ROS) production and decreased antioxidant levels lead to the induction of oxidative stress, which plays a pivotal role in the pathological process of neonatal HIE. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key endogenous antioxidant transcription factor that protects against oxidative stress by promoting the transcription of various antioxidant genes. It has been demonstrated that Nrf2 signaling pathway activation by different compounds may protect against neonatal HIE. This review outlines the role of oxidative stress in neonatal HIE and summarizes the impact of antioxidants on neonatal HIE via activation of the Nrf2 signaling pathway. In conclusion, Nrf2 signaling pathway potentially exerts antioxidant, anti-inflammatory, antiapoptotic and antiferroptotic effects, thereby emerging as a focal point for future neonatal HIE treatment strategies.
The invention provides a traditional Chinese medicine composition having an effect of inhibiting tumor-related cytokines. The traditional Chinese medicine composition is prepared from 12 to 18 portions by weight of radix astragali, 8 to 12 portions by weight of glossy privet fruit, 1 to 2 portions by weight of American ginseng and 1 to 2 portions by weight of licorice root. The invention also provides a use of the traditional Chinese medicine composition in inhibition of tumor-related cytokines. The cytokines comprise PD-L1, IL-13, IL-1 and TNF. The invention also provides a method for preparing the traditional Chinese medicine composition. Through use of licorice root and American ginseng based on the traditional Chinese medicines of radix astragali and glossy privet fruit, expression of PD-L1 in tumor cells is directly inhibited and expression of cytokines such as IL-13, IL-1 and TNF is adjusted from the upstream so that an immune system is adjusted in a cell level and in a liquid level, immune functions are recovered, development of tumors is inhibited and patient survival time is prolonged. Compared with the existing monoclonal antibody, the traditional Chinese medicine composition has a lower cost and higher safety.